ATE326951T1 - Oral zersetzbare tablette mit ausbildung eines zähen schleims - Google Patents

Oral zersetzbare tablette mit ausbildung eines zähen schleims

Info

Publication number
ATE326951T1
ATE326951T1 AT99941105T AT99941105T ATE326951T1 AT E326951 T1 ATE326951 T1 AT E326951T1 AT 99941105 T AT99941105 T AT 99941105T AT 99941105 T AT99941105 T AT 99941105T AT E326951 T1 ATE326951 T1 AT E326951T1
Authority
AT
Austria
Prior art keywords
mucuus
tough
formation
orally dissolvable
dissolvable tablet
Prior art date
Application number
AT99941105T
Other languages
English (en)
Inventor
John M Siebert
Rajendra K Khankari
Unchalee Kositprapa
S Indiran Pather
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Application granted granted Critical
Publication of ATE326951T1 publication Critical patent/ATE326951T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99941105T 1998-08-12 1999-08-12 Oral zersetzbare tablette mit ausbildung eines zähen schleims ATE326951T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9626598P 1998-08-12 1998-08-12
US09/372,738 US6368625B1 (en) 1998-08-12 1999-08-11 Orally disintegrable tablet forming a viscous slurry

Publications (1)

Publication Number Publication Date
ATE326951T1 true ATE326951T1 (de) 2006-06-15

Family

ID=26791503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941105T ATE326951T1 (de) 1998-08-12 1999-08-12 Oral zersetzbare tablette mit ausbildung eines zähen schleims

Country Status (9)

Country Link
US (1) US6368625B1 (de)
EP (1) EP1104288B1 (de)
JP (1) JP2002522471A (de)
AT (1) ATE326951T1 (de)
AU (1) AU742049B2 (de)
CA (1) CA2339992C (de)
DE (1) DE69931498T2 (de)
ES (1) ES2265188T3 (de)
WO (1) WO2000009090A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
ES2273409T3 (es) 1997-03-28 2007-05-01 Eisai Co., Ltd. Medicamento oral que previene el sabor desagradable y similar.
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
JP4107842B2 (ja) * 2000-03-01 2008-06-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 ポリビニルアルコールを配合した速崩壊性錠剤
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
CN1630513A (zh) * 2002-02-04 2005-06-22 兰贝克赛实验室有限公司 流体动力平衡的以两相释放的口服药物输递系统
GB0203984D0 (en) * 2002-02-20 2002-04-03 Mach Ind Etablissements Comsumable container
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
DE10311585A1 (de) * 2003-03-14 2004-09-23 Basf Ag Wirkstoffhaltige Adsorbate
CA2518734A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
WO2004098571A1 (en) * 2003-04-30 2004-11-18 Zicam, Llc Cold remedy composition comprising zinc salts
NZ544007A (en) 2003-05-07 2009-05-31 Samyang Corp Highly plastic granules for making fast melting tablets
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
WO2005009395A2 (en) * 2003-07-23 2005-02-03 L. Perrigo Company Cellulosic fiber containing composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP4740740B2 (ja) * 2003-12-09 2011-08-03 大日本住友製薬株式会社 薬物含有粒子および該粒子を含む固形製剤
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20070036853A1 (en) * 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065318A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral opiate dosage form
ME01300B (me) * 2003-12-31 2013-12-20 Cima Labs Inc Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja
US20050170014A1 (en) * 2004-01-30 2005-08-04 Anandi Krishnan Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
WO2005074658A2 (en) * 2004-01-30 2005-08-18 Glenmark Pharmaceuticals Inc., Usa Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
JP5179757B2 (ja) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US20060003003A1 (en) * 2004-06-28 2006-01-05 Bakker Johan A Oral sustained release formulation of tedisamil with gastric retention properties
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DK1830814T3 (da) * 2005-01-06 2009-08-03 Cima Labs Inc Smagsmaskeret formulering til ikke-plastificerende lægemidler
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2008542299A (ja) * 2005-05-25 2008-11-27 トランセプト・ファーマシューティカルズ・インコーポレイテッド 真夜中不眠症の治療のための固体組成物およびその治療方法
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
TW200800142A (en) * 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
KR20080070848A (ko) * 2005-11-03 2008-07-31 레드포인트 바이오 코포레이션 히드라존 유도체 및 이의 용도
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
WO2007143676A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143675A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US7674831B2 (en) * 2006-08-22 2010-03-09 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080070865A1 (en) * 2006-09-15 2008-03-20 Redpoint Bio Corporation Triphenylphosphine oxide derivatives and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
CA2677230A1 (en) * 2007-02-02 2008-08-14 Redpoint Bio Corporation Use of a trpm5 inhibitor to regulate insulin and glp-1 release
WO2008100434A1 (en) 2007-02-09 2008-08-21 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone
EP1977746B8 (de) 2007-04-02 2014-09-24 Parkinson's Institute Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
WO2010077878A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
US20100163805A1 (en) * 2008-12-31 2010-07-01 Youngtack Shim Agent-containing media and methods therefor
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
BR112012004854A2 (pt) 2009-09-04 2015-09-01 Redpoint Bio Corp Método para intensificar um sabor doce de um edulcorante de carboidrato, para diminuir a quantidade de um edulcorante de carboidrato em um produto consumível, e para intensificar a edulcoração de um produto consumível, e, produto consumível.
BR112012006282A2 (pt) 2009-09-22 2015-09-01 Redpoint Bio Corp Forma cristalina i de rebaudiosídeo c isolada, métodos para fabricar a mesma, para purificar rebaudiosídeo c, para intensificar um sabor doce de um adoçante de carboidrato, para diminuir a quantiddae de um adoçante de carboidrato em um produto consumível, e para aumentar a doçura de um produto consumível, e, produto consumível.
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
CN105063104B (zh) 2011-08-08 2019-08-13 国际香料香精公司 用于香草醛或香草醛β-D-葡萄糖苷的生物合成的组合物和方法
US20140242177A1 (en) 2011-10-21 2014-08-28 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
PT2976072T (pt) 2013-03-22 2021-08-12 Univ Nova Southeastern Partículas finas de epinefrina e métodos de utilização das mesmas para o tratamento de afeções que reagem à epinefrina
EP3068227A4 (de) * 2013-11-11 2017-06-21 Forest Laboratories Holdings Limited Zusammensetzungen und verfahren zur behandlung von fosfomycin-dinatrium
EP2880992A3 (de) 2013-12-05 2015-06-17 International Flavors & Fragrances Inc. Rebaudiosid C und dessen als Stereoisomere als Naturprodukt-Süßkraftverstärker
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
EP3565617A1 (de) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung
JP7681884B2 (ja) 2017-12-22 2025-05-23 ゴールデン ゲイト バイオテック エス エル 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
EP3866774A4 (de) 2018-10-19 2022-07-27 Nova Southeastern University Sublinguale epinephrinzusammensetzungen mit ph-modifizierenden hilfsstoffen und penetrationsverstärkern und verfahren zu deren verwendung
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011950A (en) 1959-05-19 1961-12-05 Colgate Palmolive Co Liquid composition containing discrete gaseous bodies
US3142621A (en) 1961-11-02 1964-07-28 Ciba Geigy Corp Alginate suspensions of oral pharmaceutical compositions with improved taste qualities
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4414198A (en) 1982-04-23 1983-11-08 Joseph Michaelson Rapidly disintegrable tablet composition and method
US4454110A (en) 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8426152D0 (en) 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4687662A (en) * 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5624683A (en) 1986-08-06 1997-04-29 Eisai Co., Ltd. Sustained-release multi-granule tablet
US5288500A (en) 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US5215752A (en) 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5273823A (en) 1988-10-11 1993-12-28 The Dow Chemical Company Shaped articles containing copolymers of polybenzazoles
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5102664A (en) 1989-07-19 1992-04-07 Day Charles E Good-tasting gritty drug formulations
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EP0662320B1 (de) 1991-08-30 2001-05-30 Showa Yakuhin Kako Co., Ltd. Trockene gelzusammensetzung
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5545423A (en) 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5368862A (en) 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
US5837285A (en) * 1992-02-18 1998-11-17 Nakamichi; Kouichi Fast soluble tablet
US5422122A (en) 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
IL104283A (en) 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2732217B1 (fr) * 1995-03-29 1997-06-06 Hesnard Xavier Forme d'administration solide a usage oral
JP2919771B2 (ja) * 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
ATE297191T1 (de) * 1996-06-14 2005-06-15 Kyowa Hakko Kogyo Kk Im munde schnellzerfallende tablette
KR20050071718A (ko) * 1996-07-12 2005-07-07 다이이찌 세이야꾸 가부시기가이샤 속붕괴성 압축성형물 및 그의 제조법
FR2753097A1 (fr) * 1996-09-11 1998-03-13 Barrau Francois Gel aqueux ou hydroalcoolique extemporane a viscosite controlee
NZ334914A (en) * 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
JPH10182436A (ja) * 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
JPH10167958A (ja) * 1996-12-09 1998-06-23 Sankyo Co Ltd ロキソプロフェンナトリウム類を含有する口腔内速溶性製剤及びその製造方法
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations

Also Published As

Publication number Publication date
JP2002522471A (ja) 2002-07-23
DE69931498T2 (de) 2007-03-01
AU5482399A (en) 2000-03-06
CA2339992C (en) 2006-01-03
CA2339992A1 (en) 2000-02-24
AU742049B2 (en) 2001-12-13
US6368625B1 (en) 2002-04-09
EP1104288A4 (de) 2003-04-16
ES2265188T3 (es) 2007-02-01
DE69931498D1 (de) 2006-06-29
EP1104288A1 (de) 2001-06-06
WO2000009090A1 (en) 2000-02-24
EP1104288B1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
ATE326951T1 (de) Oral zersetzbare tablette mit ausbildung eines zähen schleims
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
WO2002067903A3 (en) Compositions and methods of manufacture for oral dissolvable dosage forms
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
ATE340563T1 (de) DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
MY118371A (en) Tetrahydrolipstatin containing compositions
EP1242013A4 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
TR200003788A2 (tr) Yavaş salımlı oral dozaj bileşim.
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
MX9700081A (es) Composiciones farmaceuticas de tacrina.
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
GEP20063856B (en) Organoleptically acceptable intraorally disintegrating compositions
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
WO2005053658A8 (en) Butylphthalide soft gel capsule and its preparatin procedure
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE361122T1 (de) Zahnpflegemittel in portionskapseln
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
ES2172481A1 (es) Composicion farmaceutica que contiene citalopram.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties